These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29605800)

  • 1. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets.
    Brixner D; Kaló Z; Maniadakis N; Kim K; Wijaya K
    Value Health Reg Issues; 2018 Sep; 16():9-13. PubMed ID: 29605800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.
    Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K
    Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.
    Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z
    BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidance toward the implementation of multicriteria decision analysis framework in developing countries.
    Inotai A; Nguyen HT; Hidayat B; Nurgozhin T; Kiet PHT; Campbell JD; Németh B; Maniadakis N; Brixner D; Wijaya K; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):585-592. PubMed ID: 30092151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers.
    Otte M; Dauben HP; Ahn J; Gutierrez Ibarluzea I; Drummond M; Simoens S; Kaló Z; Suh DC
    Expert Rev Pharmacoecon Outcomes Res; 2024 Nov; 24(9):1061-1066. PubMed ID: 39221874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
    Angelis A; Linch M; Montibeller G; Molina-Lopez T; Zawada A; Orzel K; Arickx F; Espin J; Kanavos P
    Soc Sci Med; 2020 Feb; 246():112595. PubMed ID: 31874372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework.
    Angelis A; Kanavos P
    Soc Sci Med; 2017 Sep; 188():137-156. PubMed ID: 28772164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
    Diaby V; Lachaine J
    Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendation for a Pilot MCDA Tool to Support the Value-Based Purchasing of Generic Medicines in the UAE.
    Farghaly MN; Al Dallal SAM; Fasseeh AN; Monsef NA; Suliman EAMA; Tahoun MA; Abaza S; Kaló Z
    Front Pharmacol; 2021; 12():680737. PubMed ID: 34168564
    [No Abstract]   [Full Text] [Related]  

  • 13. [HERA-QUEST: HTA evaluation of generic pharmaceutical products to improve quality, economic efficiency, patient safety and transparency in drug product changes in hospitals].
    Gyalrong-Steur M; Kellermann A; Bernard R; Berndt G; Bindemann M; Nusser-Rothermundt E; Amann S; Brakebusch M; Brüggmann J; Tydecks E; Müller M; Dörje F; Kochs E; Riedel R
    Z Evid Fortbild Qual Gesundhwes; 2017 Apr; 121():5-13. PubMed ID: 28545614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
    Tony M; Wagner M; Khoury H; Rindress D; Papastavros T; Oh P; Goetghebeur MM
    BMC Health Serv Res; 2011 Nov; 11():329. PubMed ID: 22129247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
    Marsh KD; Sculpher M; Caro JJ; Tervonen T
    Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-criteria development and incorporation into decision tools for health technology adoption.
    Poulin P; Austen L; Scott CM; Waddell CD; Dixon E; Poulin M; Lafrenière R
    J Health Organ Manag; 2013; 27(2):246-65. PubMed ID: 23802401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
    Kolasa K; Zwolinski KM; Kalo Z; Hermanowski T
    Orphanet J Rare Dis; 2016 Mar; 11():23. PubMed ID: 26965710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
    Holtorf AP; Gialama F; Wijaya KE; Kaló Z
    Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.